Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 20/20 | 0.84 |
| ▸ | CHRM2 known ✓ | P08172 | 4/20 | 0.74 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4467207 | 1.00 | CHRM3 (0.84) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL4478085 | 0.91 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL4478087 | 0.91 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL5427006 | 0.86 | CHRM3 (0.95) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL5427001 | 0.86 | CHRM3 (0.95) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL4479393 | 0.86 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL4479391 | 0.86 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Iodide SCHEMBL4631996 | 0.84 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Iodide SCHEMBL4631992 | 0.84 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL4631645 | 0.81 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495010-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2009-02-24 | — | — | US | claimed |
| US-20060178396-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2006-08-10 | — | — | US | claimed |
| US-7495010-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2009-02-24 | — | — | US | disclosed |
| US-20060178396-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178396-A1 | Muscarinic acetylcholine receptor antagonists | CHRM3, CHRNG, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.